Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 501–600 of 1,000
Zeng, Y., Petralia, R. S., Vijayasarathy, C., Wu, Z., Hiriyanna, S., Song, H., Wang, Y., Sieving, P. A., & Bush, R. A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18920 · Cited by 39
Self-citationApplication of a New Subretinal Injection Device in the Dog
Komáromy, A. M., Varner, S. E., De Juan, E., Acland, G. M., & Aguirre, G. D. (2006) · Cell Transplantation · doi:10.3727/000000006783981701 · Cited by 37
Self-citationAAV-Mediated Gene Therapy for Retinal Disorders in Large Animal Models
Stieger, K., Lheriteau, E., Moullier, P., & Rolling, F. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.206 · Cited by 37
Adeno-Associated Viral Vectors and the Retina
Alexander, J. J., & Hauswirth, W. W. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_13 · Cited by 44
Self-citationCorrection of Monogenic and Common Retinal Disorders with Gene Therapy
Sengillo, J., Justus, S., Cabral, T., & Tsang, S. (2017) · Genes · doi:10.3390/genes8020053 · Cited by 37
“Later, in 2001, injection of an adeno-associated virus (AAV) delivering subretinal RPE65 to an RPE65−/− canine model was reported to delay disease progression and even restore visual function [4].”
MethodMaria, M., Ajmal, M., Azam, M., Waheed, N. K., Siddiqui, S. N., Mustafa, B., Ayub, H., Ali, L., Ahmad, S., Micheal, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119806 · Cited by 39
“For example, AAV-based gene therapy has been shown to be successful in a CRD dog model and in humans with RPE65-associated LCA [52–57], as well as in choroideremia subjects [58].”
BackgroundGarcia, M. M., Ying, G.-S., Cocores, C. A., Tanaka, J. C., & Komáromy, A. M. (2010) · American Journal of Veterinary Research · doi:10.2460/ajvr.71.1.97 · Cited by 40
Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy
Kang, C., & Scott, L. J. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00475-6 · Cited by 43
“Electrophysiological responses were also improved in a canine model [14].”
BackgroundBuilding the bionic eye: an emerging reality and opportunity
Merabet, L. B. (2011) · Progress in brain research · doi:10.1016/b978-0-444-53355-5.00001-4 · Cited by 42
Guziewicz, K. E., Slavik, J., Lindauer, S. J., Aguirre, G. D., & Zangerl, B. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6385 · Cited by 39
Self-citationThe genetics of eye disorders in the dog
Mellersh, C. S. (2014) · Canine Genetics and Epidemiology · doi:10.1186/2052-6687-1-3 · Cited by 52
Impact of Retinal Disease-Associated RPE65 Mutations on Retinoid Isomerization
Bereta, G., Kiser, P. D., Golczak, M., Sun, W., Heon, E., Saperstein, D. A., & Palczewski, K. (2008) · Biochemistry · doi:10.1021/bi800905v · Cited by 36
Rakoczy, P. E., Brankov, M., Fonceca, A. M., Zaknich, T., Rae, B. C., & Lai, C. (2003) · Diabetes · doi:10.2337/diabetes.52.3.857 · Cited by 36
“The use of an adenoassociated viral vector could overcome the problem, as it could maintain long-term VEGF expression without evoking an immune response (31).”
BackgroundSachs, H. G., Schanze, T., Brunner, U., Sailer, H., & Wiesenack, C. (2005) · Journal of Neural Engineering · doi:10.1088/1741-2560/2/1/008 · Cited by 36
Jacobs, J. B., Dell’Osso, L. F., Hertle, R. W., Acland, G. M., & Bennett, J. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1233 · Cited by 36
Self-citationAAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice
Choi, V. W., Bigelow, C. E., McGee, T. L., Gujar, A. N., Li, H., Hanks, S. M., Vrouvlianis, J., Maker, M., Leehy, B., Zhang, Y., et al. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.22 · Cited by 35
Lee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
Nanotechnology for ocular therapeutics and tissue repair
Raju, H. B., & Goldberg, J. L. (2008) · Expert Review of Ophthalmology · doi:10.1586/17469899.3.4.431 · Cited by 36
Blood Flow Magnetic Resonance Imaging of Retinal Degeneration
Li, Y., Cheng, H., Shen, Q., Kim, M., Thulé, P. M., Olson, D. E., Pardue, M. T., & Duong, T. Q. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2188 · Cited by 35
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Adeno-Associated Virus Mediated Gene Therapy for Retinal Degenerative Diseases
Stieger, K., Cronin, T., Bennett, J., & Rolling, F. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_8 · Cited by 35
Self-citationSanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 43
“AAV2/2mediated delivery of RPE65 led to the long-term restoration of vision in treated dogs [29].”
Retinal Gene Delivery by rAAV and DNA Electroporation
Venkatesh, A., Ma, S., Langellotto, F., Gao, G., & Punzo, C. (2013) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc14d04s28 · Cited by 35
A Novel Method for Objective Vision Testing in Canine Models of Inherited Retinal Disease
Gearhart, P. M., Gearhart, C., & Petersen‐Jones, S. M. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0625 · Cited by 38
“The RPE65 mutant dogs have an absence of rpe65 protein in the retinal pigment epithelium.(2) Extrapolation from studies in RPE65 mutant mice shows that it is very likely that in the RPE65 mutant dogs there is a lack of 11-cis retinal supply to the photoreceptors, resulting in very reduced function of both and rods and…”
BackgroundRomán, A. J., Sl, B., Alemán, T. S., Jj, P., McDowell, J. H., Se, B., Cideciyan, A. V., Jacobson, S. G., & Hauswirth, W. (2007) · PubMed · Cited by 36
Self-citationSandalon, Z., Bruckheimer, E. M., Lustig, K., Rogers, L. C., PELUSO, R. W., & Burstein, H. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12355-12365.2004 · Cited by 37
“Recombinant adeno-associated virus (AAV) vector is one of the most promising delivery vehicles under development for gene therapy which has been shown to efficiently direct longterm transgene expression in multiple tissues, including skeletal muscle, liver, brain, and retina, with little or no inflammation or cellular…”
BackgroundAtkinson, C. L., Feng, J., & Zhang, D.-Q. (2012) · Journal of Neurophysiology · doi:10.1152/jn.00786.2012 · Cited by 35
“Promising strategies for vision restoration include photoreceptor cell transplantation, stem cell and gene therapy, and electrical and cell type-specific optical stimulation (Acland et al. 2001; Bi et al. 2006; Pearson et al. 2012; Weiland et al. 2005).”
BackgroundAnnear, M. J., Mowat, F. M., Bartoe, J. T., Querubin, J., Azam, S. A., Basche, M., Curran, P. G., Smith, A. J., Bainbridge, J. W. B., Ali, R. R., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.146 · Cited by 34
“The initial proof-of-principle studies in young Rpe65-deficient dogs showed that subretinally delivered recombinant adeno-associated viral (rAAV) vectors expressing either human or canine RPE65 dramatically improved photoreceptor function as assessed by ERG, vision-testing performance, and retinal-mediated visual cort…”
The use of nonhuman primates in studies of noise injury and treatment
Burton, J. A., Valero, M. D., Hackett, T. A., & Ramachandran, R. (2019) · The Journal of the Acoustical Society of America · doi:10.1121/1.5132709 · Cited by 39
“In earlier stages of development, the procedure was refined and vetted in rodents, then applied to a large-animal canine model for further validation (Acland et al., 2001).”
MethodMiyadera, K., Kato, K., Boursnell, M. E. G., Mellersh, C. S., & Sargan, D. R. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9384-9 · Cited by 35
“Of the genes within the second RD interval, LRAT is a strong candidate gene based on its involvement in severe EORDs in human patients (Thompson et al. 2001).”
InfluentialA novel mutation in TTC8 is associated with progressive retinal atrophy in the golden retriever
Downs, L. M., Wallin‐Håkanson, B., Bergström, T. F., & Mellersh, C. S. (2014) · Canine Genetics and Epidemiology · doi:10.1186/2052-6687-1-4 · Cited by 35
“Further to this, canine models for human eye diseases have proved invaluable in gene-therapy studies, most notably the canine model of LCA associated with RPE65 [13-17].”
BackgroundKoenekoop, R. K., Fishman, G. A., Iannaccone, A., Ezzeldin, H., Ciccarelli, M. L., Baldi, A., Sunness, J. S., Lotery, A. J., Jablonski, M. M., Pittler, S. J., et al. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1325 · Cited by 36
Genetic Animal Models for Retinal Degeneration
Fauser, S., Luberichs, J., & Schüttauf, F. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00314-4 · Cited by 39
Iwabe, S., Ying, G., Aguirre, G. D., & Beltran, W. A. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.04.006 · Cited by 34
Self-citationRevolution in Gene Medicine Therapy and Genome Surgery
Jiang, D. J., Xu, C. L., & Tsang, S. H. (2018) · Genes · doi:10.3390/genes9120575 · Cited by 35
“It was first demonstrated in 1996 to successfully rescue photoreceptor cells in a retinal degeneration mouse model, and a few years later to rescue retinal function in Leber congenital amaurosis (LCA) canine models [9,10].”
BackgroundHuman Induced Pluripotent Stem Cells As a Tool to Model a Form of Leber Congenital Amaurosis
Lustremant, C., Habeler, W., Plancheron, A., Goureau, O., Grenot, L., de la Grange, P., Audo, I. S., Nandrot, E. F., & Monville, C. (2013) · Cellular Reprogramming · doi:10.1089/cell.2012.0076 · Cited by 36
“replacement clinical trials have commenced (Acland et al., 2001; Ali et al., 2000; Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008, 2009; Simonelli et al., 2010; Stieger et al., 2011).”
BackgroundGene Therapy for Leber Congenital Amaurosis
Dejneka, N. S., Surace, E. M., & Bennett, J. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0067-4_53 · Cited by 32
Self-citationSapieha, P. S., Hauswirth, W. W., & Polo, A. D. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20803 · Cited by 34
“This difference likely is due to increased gene expression driven by the CMV enhancer/CbA promoter combination (Acland et al., 2001), leading to higher levels of FGF-2 transgenic protein.”
BackgroundSelf-citationProspects and problems of gene therapy: an update
Górecki, D. C. (2001) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.6.2.187 · Cited by 33
Weleber, R. G., Kurz, D. E., & Trzupek, K. M. (2003) · Ophthalmology Clinics of North America · doi:10.1016/s0896-1549(03)00072-5 · Cited by 33
“Acland et al [72] delivered a recombinant AAV carrying wild-type RPE65 to three affected dogs and tested efficacy with electroretinography.”
MethodOcular genetics: current understanding
MacDonald, I. M., Tran, M., & Musarella, M. A. (2004) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2003.12.003 · Cited by 36
Seggern, D. J. V., Aguilar, E., Kinder, K., Fleck, S. K., Armas, J. C. G., Stevenson, S. C., Ghazal, P., Nemerow, G. R., & Friedlander, M. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00030-8 · Cited by 33
O’Brien, S. J., & Murphy, W. J. (2003) · Science · doi:10.1126/science.1090531 · Cited by 32
Acute Radiolabeling of Retinoids in Eye Tissues of Normal and Rpe65-Deficient Mice
Qtaishat, N. M., Redmond, T. M., & Pepperberg, D. R. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0679 · Cited by 32
Kijas, J., Zangerl, B., Miller, B., Nelson, J., Kirkness, E. F., Aguirre, G. K., & Acland, G. M. (2004) · PubMed · Cited by 32
Self-citationRPE65 surface epitopes, protein interactions, and expression in rod- and cone-dominant species.
Hemati, N., Feathers, K. L., Chrispell, J. D., Reed, D. M., Carlson, T. J., & Thompson, D. A. (2005) · PubMed · Cited by 34
Ofri, R., Averbukh, E., Ezra-Elia, R., Ross, M., Honig, H., Obolensky, A., Rosov, A., Hauswirth, W. W., Gootwine, E., & Banin, E. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.076 · Cited by 31
“15 To the best of our knowledge, gene augmentation therapy has not been reported in the canine CNGA3 achromatopsia model, but it has been reported in the canine CNGB3 achromatopsia model, where gene therapy using AAV5 was found to rescue cone function for at least 33 months.”
Self-citationStem cell biology and cell transplantation therapy in the retina
Osakada, F., Hirami, Y., & Takahashi, M. (2009) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-26-297 · Cited by 31
“These adverse effects can be avoided using selected serotypes of rAAV vectors (Hoffman et al., 1997). rAAV-mediated gene therapy in canine models (Acland et al., 2001), and clinical trials on Leber’s congenital amaurosis, a congenital form of RP (Bainbridge et al., 2008; Maguire et al., 2008).”
BackgroundVoretigene Neparvovec and Gene Therapy for Leber’s Congenital Amaurosis: Review of Evidence to Date
Padhy, S. K., Takkar, B., Narayanan, R., Venkatesh, P., & Jalali, S. (2020) · The Application of Clinical Genetics · doi:10.2147/tacg.s230720 · Cited by 38
Gucy2f zebrafish knockdown – a model for Gucy2d-related leber congenital amaurosis
Stiebel‐Kalish, H., Reich, E., Rainy, N., Vatine, G. D., Nisgav, Y., Tovar, A., Gothilf, Y., & Bach, M. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.10 · Cited by 34
Retinal Degenerations: From Cell Signaling to Cell Therapy; Pre-Clinical and Clinical Issues
Cronin, T., Léveillard, T., & Sahel, J. (2007) · Current Gene Therapy · doi:10.2174/156652307780363143 · Cited by 31
Gene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
Bruewer, A. R., Mowat, F. M., Bartoe, J. T., Boye, S. L., Hauswirth, W. W., & Petersen-Jones, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060218 · Cited by 29
“For example dogs with a spontaneous mutation in the Rpe65 gene were pivotal in the development of phase I/II clinical trial programs for treatment of patients with mutations in the RPE65 gene, an important cause of LCA [5].”
BackgroundSelf-citationGene replacement therapy for retinal CNG channelopathies
Schön, C., Biel, M., & Michalakis, S. (2013) · Molecular Genetics and Genomics · doi:10.1007/s00438-013-0766-4 · Cited by 34
“Treated LCA-patients showed substantial visual improvement in the short term and no decline from this new level for at least 3 years, whereas photoreceptor degeneration progresses unabated (Cideciyan et al. 2013; Jacobson et al. 2012).”
InfluentialMiyadera, K., Santana, E., Roszak, K. P., Iffrig, S., Visel, M., Iwabe, S., Boyd, R. F., Bartoe, J. T., Sato, Y., Gray, A. P., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117038119 · Cited by 32
Self-citationNarfström, K. L., Deckman, K. H., & Menotti-Raymond, M. A. (2011) · Journal of Ophthalmology · doi:10.1155/2011/906943 · Cited by 35
“[66], using AAV2/2 as a safe and effective vector.”
MethodYu, W., Grzywacz, N. M., Lee, E.-J., & Field, G. D. (2017) · Journal of Neurophysiology · doi:10.1152/jn.00826.2016 · Cited by 30
“The retention of functionally distinct RGCs following rod death lends support to the idea that rod photoreceptor replacement may largely restore vision (Acland et al. 2001; Bakondi et al. 2016; Bennett et al. 2012; MacLaren et al. 2006; Tucker et al. 2011).”
BackgroundResultGeneration of genetically-engineered animals using engineered endonucleases
Lee, J. G., Sung, Y. H., & Baek, I. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1037-z · Cited by 35
“Indeed, dogs have proven remarkable model systems to investigate various hereditary human diseases including leukocyte adhesion deficiency, Leber’s congenital amaurosis, Duchenne muscular dystrophy, and hemophilia A and B (Bauer and Hickstein 2000; Acland et al. 2001; Kinali et al. 2009; Margaritis 2010) because they…”
BackgroundDavies, J. B., Ciavatta, V. T., Boatright, J. H., & Nickerson, J. M. (2003) · PubMed · Cited by 35
Ford, M. M., Bragadóttir, R., Rakoczy, P. E., & Narfström, K. L. (2003) · Documenta Ophthalmologica · doi:10.1023/a:1024431827812 · Cited by 35
“(rAAV-RPE65) construct in three RPE65 null mutation dogs restored functional vision [10].”
BackgroundImplantation and testing of subretinal film electrodes in domestic pigs
Schanze, T., Sachs, H. G., Wiesenack, C., Brunner, U., & Sailer, H. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.07.007 · Cited by 33
Nojima, S., Toyofuku, T., Kamao, H., Ishigami, C., Kaneko, J., Okuno, T., Takamatsu, H., Ito, D., Kang, S., Kimura, T., et al. (2013) · Nature Communications · doi:10.1038/ncomms2420 · Cited by 27
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis
Stein, L., Roy, K., Lei, L., & Kaushal, S. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.557358 · Cited by 35
“In the first of many proof-of-concept studies conducted in the spontaneously occurring RPE65 null canines, three dogs were injected either subretinally or intravitreally with AAV2-vectored wild-type dog RPE65 cDNA with a CMV/CBA promoter at 4 months of age [8].”
BackgroundMethodAdvancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space
Wakshull, E., Quarmby, V. E., Mahler, H., Rivers, H. M., Jere, D., Ramos, M. F., Szczesny, P. J., Bechtold-Peters, K., Masli, S., & Gupta, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0128-y · Cited by 29
Kumaran, N., Rubin, G. S., Kalitzeos, A. A., Fujinami, K., Bainbridge, J. W., Weleber, R. G., & Michaelides, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-23873 · Cited by 31
“Importantly, it is also better placed to quantify both global and local pointwise parameters (including, mean sensitivity, mean deviation, and volumetric measures), which allow the investigation of regions of interest by topographic isosensitivity or by geographic selections.(7) Of note, the resolution of static perim…”
BackgroundYang, U., Gentleman, S., Gai, X., Gorin, M. B., Borchert, M., Lee, T. C., Villanueva, A., Koenekoop, R. K., Maguire, A. M., Bennett, J., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.3914 · Cited by 29
Self-citationTreating Bietti crystalline dystrophy in a high-fat diet-exacerbated murine model using gene therapy
Qu, B., Wu, S., Jiao, G., Zou, X., Li, Z., Guo, L., Sun, X., Huang, C., Sun, Z., Zhang, Y., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-0159-3 · Cited by 32
“There are plenty of clinical evidences showing that AAV is nonpathogenic and causing minimal immune responses in humans [28, 31, 32].”
BackgroundCurrent status and applications of somatic cell nuclear transfer in dogs
Jang, G., Kim, M., & Lee, B. C. (2010) · Theriogenology · doi:10.1016/j.theriogenology.2010.05.036 · Cited by 34
Huszthy, P. C., Engelsen, A. S. T., Wilson, J. M., Kotin, R. M., Lønning, P. E., Bjerkvig, R., & Hoover, F. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.381 · Cited by 32
“AAV2 vectors have shown efficacy in large animal disease models following local administration (Schimmenti et al., 1998; Bankiewicz et al., 2000; Rudich et al., 2000; Acland et al., 2001; Beaty et al., 2002; Martin et al., 2002; Mount et al., 2002; Muramatsu et al., 2002).”
Anatomical evidence of photoreceptor degeneration induced by iodoacetic acid in the porcine eye
Scott, P. A., Kaplan, H. J., & Sandell, J. H. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.06.017 · Cited by 31
Potential Therapeutic Agents Against Retinal Diseases Caused by Aberrant Metabolism of Retinoids
Liu, X., Chen, J., Liu, Z., Li, J., Yao, K., & Wu, Y. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18429 · Cited by 32
Gene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 29
Chapter 17 – Retinitis Pigmentosa and Allied Disorders
Weleber, R., & Gregory-Evans, K. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-02598-0.50023-9 · Cited by 16
Recombinant adeno-associated virus targets passenger gene expression to cones in primate retina
Mancuso, K., Hendrickson, A. E., Connor, Jr., Mauck, M. C., Kinsella, J. J., Hauswirth, W. W., Neitz, J., & Neitz, M. (2007) · Journal of the Optical Society of America A · doi:10.1364/josaa.24.001411 · Cited by 29
Self-citationThe Ocular Gene Delivery Landscape
Sahu, B., Chug, I., & Khanna, H. (2021) · Biomolecules · doi:10.3390/biom11081135 · Cited by 28
Using Stem Cells to Model Diseases of the Outer Retina
Yvon, C., Ramsden, C. M., Lane, A., Powner, M. B., da Cruz, L., Coffey, P. J., & Carr, A. F. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.05.001 · Cited by 34
Li, Y., Li, J., Chen, B., Chen, Q., Zhang, G., Liu, S., & Ge, Z. (2014) · Biomacromolecules · doi:10.1021/bm500532x · Cited by 28
Clérin, E., Marussig, M., Sahel, J., & Léveillard, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051625 · Cited by 33
A Microparticle/Hydrogel Combination Drug-Delivery System for Sustained Release of Retinoids
Gao, S.-Q., Maeda, T., Okano, K., & Palczewski, K. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10279 · Cited by 30
“This strategy has been used successfully in LCA animal models (mice and dogs), and its positive effect was sustained for several years after a single treatment in RPE65-null dogs.(63,64) Recently, the first LCA patients were enrolled for gene therapy.”
MethodBlood flow and anatomical MRI in a mouse model of retinitis pigmentosa
Muir, E. R., Garza, B. H. D. L., & Duong, T. Q. (2012) · Magnetic Resonance in Medicine · doi:10.1002/mrm.24232 · Cited by 30
“(13), and stem cell therapy (14), show potential to slow, halt, or reverse retinal degeneration.”
BackgroundNusinowitz, S., Ridder, W. H., Pang, J., Chang, B., Noorwez, S. M., Kaushal, S., Hauswirth, W. W., & Heckenlively, J. R. (2006) · Vision Research · doi:10.1016/j.visres.2006.05.010 · Cited by 29
“vector carrying a wild-type canine RPE65 cDNA restored retinal function in this animal model (Acland et al., 2001).”
Self-citationMannermaa, E., Rönkkö, S., Ruponen, M., Reinisalo, M., & Urtti, A. O. (2005) · Current Eye Research · doi:10.1080/02713680590934058 · Cited by 28
Gene Therapy for Genetic and Acquired Retinal Diseases
Chaum, E., & Hatton, M. P. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00336-3 · Cited by 33
Improvement in vision: a new goal for treatment of hereditary retinal degenerations
Jacobson, S. G., Cideciyan, A. V., Aguirre, G. D., Román, A. J., Sumaroka, A., Hauswirth, W. W., & Palczewski, K. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1030393 · Cited by 31
“Subretinal gene therapy improved visual function in three RPE65-mutant dogs using a recombinant adeno-associated virus (AAV) vector-carrying wild-type canine RPE65 cDNA [38].”
MethodSelf-citationCai, B., Sun, S., Li, Z., Zhang, X., Ke, Y., Yang, J., & Li, X. (2018) · Human Genetics · doi:10.1007/s00439-018-1933-9 · Cited by 30
The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease
Velazquez, L. A. M., & Ballios, B. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111542 · Cited by 28
“Before gene therapies for retinal disease could be developed, researchers had established animal models in multiple species including rodents [88,89] and the Briard dogs [90,91] that led to the understanding of the physiologic role of the RPE65 enzyme in visual function and disease.”
BackgroundMethodNarfström, K. L., Wrigstad, A., Ekesten, B., & Berg, A. ‐. (2007) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2007.00527.x · Cited by 28
Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision
Karamali, F., Behtaj, S., Abraki, S. B., Hadady, H., Atefi, A., Savoj, S., Soroushzadeh, S., Najafian, S., Nasr‐Esfahani, M. H., & Klassen, H. J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03738-4 · Cited by 27
Gene Therapy Regenerates Protein Expression in Cone Photoreceptors in Rpe65R91W/R91W Mice
Kostic, C., Crippa, S. V., Pignat, V., Bemelmans, A.-P., Samardzija, M., Grimm, C., Wenzel, A., & Arsenijevic, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016588 · Cited by 26
Yeh, C. Y., Koehl, K. L., Harman, C. D., Iwabe, S., Guzman, J. M., Petersen‐Jones, S. M., Kardon, R. H., & Komáromy, A. M. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19865 · Cited by 32
Recent advances in ocular gene therapy
Chung, D. C., Lee, V., & Maguire, A. M. (2009) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32832f802a · Cited by 30
Self-citationHojo, M., Abe, T., Sugano, E., Yoshioka, Y., Saigo, Y., Tomita, H., Wakusawa, R., & Tamai, M. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0059 · Cited by 30
Le chien, un modèle pour la génétique des mammifères
Galibert, F., André, C., & Hitte, C. (2004) · médecine/sciences · doi:10.1051/medsci/2004208-9761 · Cited by 31
Nakazawa, M., Hara, A., & Ishiguro, S.-I. (2019) · BioMed Research International · doi:10.1155/2019/8276140 · Cited by 29
Can Ultrasound Solve the Transport Barrier of the Neural Retina?
Peeters, L., Lentacker, I., Vandenbroucke, R. E., Lucas, B., Demeester, J., Sanders, N. N., & Smedt, S. C. D. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9684-2 · Cited by 25
of the Retina in the 4 Years Following rAAV-mediated Gene Transfer in the RPE65 Null Mutation Dog
Narfstro¨m, K., Seeliger, M. W., Lai, C., Vaegan, Katz, M. L., Rakoczy, E. P., & Remé, C. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_15 · Cited by 28
Gu, D., Beltran, W. A., Li, Z., Acland, G. M., & Aguirre, G. K. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0428 · Cited by 25
Self-citationLeber Congenital Amaurosis: Disease, Genetics and Therapy
Ahmed, E., & Loewenstein, J. I. (2008) · Seminars in Ophthalmology · doi:10.1080/08820530701745215 · Cited by 25
Semple‐Rowland, S. L., Eccles, K. S., & Humberstone, E. J. (2007) · PubMed · Cited by 25
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.